StockWatch
·
SHADOWFAX · Q2 FY27 · PREVIEW

Execution on Momentum — Q2 FY27 Shapes FY27 Raised Guide

Shadowfax raised FY27 revenue growth to 38–40% on a blisteringly strong Q1. On October 29, we'll see if Q2 sustains the pace and margins, whilst the new Channel Partner Program rolls out in Tier 2—a material optionality for medium-term growth.

Q2 FY27 resultsSHADOWFAXShadowfax Technologies Ltd25 Oct 2026 · 3 min read

The Setup: Momentum After a Breakout Q1

Shadowfax delivered a stunning Q1 FY27—₹1,358 Cr revenue (+65% YoY), ₹65.4 Cr profit (8× YoY), an all-time high for both. Management raised FY27 guidance from 35% to 38–40% revenue growth. The Street is watching two things in Q2: (1) Does the 65% momentum hold or moderate into the 40s? (2) Do margins stay at Q1's expanded level, or is there seasonality/investment cost as the Channel Partner Program rolls out?

Q2 Revenue (on-plan)

~₹350–380 Cr

On 38–40% FY growth trajectory from ~₹825 Cr FY26 base

PAT (expect Q1 parity)

~₹60–70 Cr

Q1 ₹65.4 Cr; assume margin hold, not expansion

Key swing factor

Volume mix & channel ramp

E-commerce flows vs. assisted SMB sales; Tier 2 costs

FII/DII sentiment

FII 8.78%, DII 19.10%

FII +1.13 pp QoQ; asset allocation moving in

On Track: The Guidance Raise Frames the Quarter

Shadowfax's 38–40% FY27 guidance is credible: Q1 delivered 65%, so a moderation into the high 30s/low 40s for the full year is plausible on a larger base. The company's trajectory (₹782 Cr FY26 → ₹1,358 Cr Q1 FY27 annualized) shows consistent acceleration. A strong Q2 print would mean revenue above ₹360 Cr and PAT maintaining Q1's pace (₹65+ Cr), signalling margin durability as the platform scales. A weak Q2 would show below-plan revenue (sub-₹340 Cr) or margin compression into mid-40s %, indicating execution friction from the Channel Partner pivot or platform-mix pressure.

Since Last Quarter: Filings & Corporate Action

Key Items to Track
  • 1 · NewQuest Asia Stake Reduction

    NewQuest Asia Fund IV sold ~15 Cr shares between July and October 2026 (bulk deals ₹204–₹287/share), reducing stake from ~25% to ~5%. No regulatory pressure, but signals rotation away from an early-stage investor. Fundraise/exit—worth a call Q&A.

  • 2 · Channel Partner Program Ramp (Strategic Positive)

    Launched September 3, 2026. Target: 1,000 partners across Tier 1–2 over 3 years, with first walk-in stores in Chandigarh and Lucknow. Could unlock SMB/mid-market TAM. On Q2, expect colour on onboarding pace, unit economics, and contribution run-rate for H2 FY27.

  • 3 · CPO Resignation (Operational)

    Nitesh Lohiya, Chief Product Officer, resigned July 31, 2026. Non-founder, so likely a role realignment rather than a governance signal. Monitor for any interim gap or strategy shift on product/platform roadmap in the call.

  • 4 · Auditor Change (Routine)

    S.R. Batliboi & Associates LLP appointed as statutory auditor from AGM (September 1) for 5 years. Routine post-IPO reshuffle; no accounting concerns flagged.

  • 5 · CIN Corporate Change (Housekeeping)

    CIN changed from U72300KA2015PLC150324 to L72300KA2015PLC150324 (October 14, 2026). Status/description code update; no operational impact.

  • 6 · ESOP Grants

    100,000 and 3,333 stock options granted July–August at ₹10/share. Modest equity incentive; routine for IPO-stage talent retention.

What to Watch on October 29

1. Revenue guidance cadence: Is FY27 growth trending ≥38% or slowing? Q2 number is the test. Anything below ₹340 Cr would flag deceleration risk. 2. Margin durability: PAT as a % of revenue. Q1 was 4.8% (₹65.4 / ₹1,358). If Q2 PAT falls below ₹55 Cr on ₹360 Cr revenue, margin compression is signalled. 3. Channel Partner early numbers: Traction on Tier 2 onboarding, GMV, and any guidance on run-rate contribution. 4. NewQuest exit context: Management colour on why and what comes next (capital deployment, M&A, buyback).

Shadowfax is in a strong execution phase—Q1 was a breakout, the FY27 guide was raised, and the Channel Partner initiative opens a new growth vector into mid-market and Tier 2. Q2 is the stamina test: can the company sustain 40%+ revenue growth, hold or grow margins, and demonstrate early validation of the partner model? The Street is already priced in a Strong Buy (5.4% upside), so execution matters more than sentiment. A beat on both revenue and margin would re-rate higher; a miss on either would test support near ₹260. Look for confidence in the 1,000-partner pipeline and margin floor for FY27.

Informational and educational content only. Not investment advice.